A new real-world study compared the health care resource utilization and costs between patients treated for multiple myeloma with and without renal impairment. READ MORE
A new real-world study compared the health care resource utilization and costs between patients treated for multiple myeloma with and without renal impairment.
Older age, African American race, and low socioeconomic status may be linked with a reduced likelihood of receiving multiple myeloma treatment of any kind.
In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.
In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
The American Society of Clinical Oncology released a clinical practice guideline update on the role of bone-modifying agents in patients with active symptomatic multiple myeloma.
From December 9-12, 2017, the American Society of Hematology hosted its Annual Meeting and Exposition in Atlanta, Georgia. The meeting provided an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field.